SEMAGLUTIDE SM5 (SM5 SM10 SM15 SM20 SM30)

Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription GLP-1 medication used for weight loss and weight management, type 2 diabetes treatment, or to reduce the risk of chronic kidney disease and major cardiovascular events in certain patients with type 2 diabetes. Semaglutide (Wegovy) is also used to treat metabolic dysfunction-associated steatohepatitis (MASH), without cirrhosis of the liver.

Semaglutide injections are self-administered once weekly as an injection under the skin, and semaglutide pills are taken once daily.

Semaglutide works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a GLP-1 receptor agonist that mimics the behavior of the GLP-1 hormone, which is naturally released after eating.

Semaglutide brand names are Ozempic, Rybelsus, and Wegovy, all made by Novo Nordisk. There is no generic semaglutide available. Semaglutide FDA approval was first granted on December 5, 2017, for the brand Ozempic.